| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -51.6 | -29.4 |
| EPS (diluted, $ a share) | $-0.97 | $-37.18 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MPLT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
MapLight Therapeutics, Inc.: key numbers
- Share price
- $6.90Close, Nov 16
- Market cap
- $293M
- Shares outstanding
- 42.44MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from MapLight Therapeutics, Inc.
All →MapLight Therapeutics Capital Raise
MapLight Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program. The company may sell up to $100 million of its common stock from time to time, with Leerink acting as the sales agent for a commission of up to 3.0%.
- Counterparty
- Leerink Partners LLC
MapLight Therapeutics Financial Results
MapLight Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, including plans for its Phase 3 ZEPHYR-2 trial in schizophrenia. The company ended the quarter with $463.4 million in cash, which is expected to fund operations through 2028 and key clinical readouts.
- Term
- Q3 2026
“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market.”
Chris Kroeger, Co-Founder and Chief Executive Officer
“We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”
Chris Kroeger, Co-Founder and Chief Executive Officer
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer Sells $96K of Stock
Anatol Kreitzer, Chief Discovery Officer, sold 12,248 shares of MapLight Therapeutics, Inc. at $7.84 a share, worth $96K in total on Oct 15, 2026. Shares held after the trade: 168,678 (-6.8%).
- Value
- $96K
- Shares
- 12,248
- Price
- $7.84
- Role
- Chief Discovery Officer
- Holding change
- -6.8%
- Trade date
- Oct 15, 2026
MapLight Therapeutics CMO Erin Pennock Foff Sells $124K of Stock
Erin Pennock Foff, CMO, sold 15,355 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $124K in total on Oct 15, 2026. Shares held after the trade: 296,906 (-4.9%).
- Value
- $124K
- Shares
- 15,355
- Price
- $8.08
- Role
- CMO
- Holding change
- -4.9%
- Trade date
- Oct 15, 2026
MapLight Therapeutics General Counsel Kristopher Hanson Sells $72.9K of Stock
Kristopher Hanson, General Counsel, sold 9,020 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $72.9K in total on Oct 15, 2026. Shares held after the trade: 128,024 (-6.6%).
- Value
- $72.9K
- Shares
- 9,020
- Price
- $8.08
- Role
- General Counsel
- Holding change
- -6.6%
- Trade date
- Oct 15, 2026
MapLight Therapeutics CAO and Interim CFO Jonathan Gillis Sells $82.1K of Stock
Jonathan Gillis, CAO and Interim CFO, sold 10,167 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $82.1K in total on Oct 15, 2026. Shares held after the trade: 142,315 (-6.7%).
- Value
- $82.1K
- Shares
- 10,167
- Price
- $8.08
- Role
- CAO and Interim CFO
- Holding change
- -6.7%
- Trade date
- Oct 15, 2026